NVCR Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -19.71% compared to NovoCure's net margin of --. NovoCure's return on equity of -40.75% beat Perspective Therapeutics's return on equity of --.

NovoCure has a consensus price target of --, signalling upside risk potential of 14.79%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 414.33%. Given that Perspective Therapeutics has higher upside potential than NovoCure, analysts believe Perspective Therapeutics is more attractive than NovoCure.

NovoCure has a beta of 0.748, which suggesting that the stock is 25.16% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $155.1M, which are larger than Perspective Therapeutics quarterly revenues of --. NovoCure's net income of -$30.6M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, NovoCure's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 5.67x versus 16.96x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -19.71% compared to NovoCure's net margin of 8.28%. NovoCure's return on equity of -40.75% beat Globus Medical's return on equity of 2.27%.

NovoCure has a consensus price target of --, signalling upside risk potential of 14.79%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 13.39%. Given that NovoCure has higher upside potential than Globus Medical, analysts believe NovoCure is more attractive than Globus Medical.

NovoCure has a beta of 0.748, which suggesting that the stock is 25.16% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $155.1M, which are smaller than Globus Medical quarterly revenues of $625.7M. NovoCure's net income of -$30.6M is lower than Globus Medical's net income of $51.8M. Notably, NovoCure's price-to-earnings ratio is -- while Globus Medical's PE ratio is 124.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 5.67x versus 4.60x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of -19.71% compared to NovoCure's net margin of 20.32%. NovoCure's return on equity of -40.75% beat LeMaitre Vascular's return on equity of 13.37%.

NovoCure has a consensus price target of --, signalling upside risk potential of 14.79%. On the other hand LeMaitre Vascular has an analysts' consensus of $98.78 which suggests that it could grow by 8.1%. Given that NovoCure has higher upside potential than LeMaitre Vascular, analysts believe NovoCure is more attractive than LeMaitre Vascular.

NovoCure has a beta of 0.748, which suggesting that the stock is 25.16% less volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.665%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.7% to investors and pays a quarterly dividend of $0.16 per share. NovoCure pays -- of its earnings as a dividend. LeMaitre Vascular pays out 41.35% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

NovoCure quarterly revenues are $155.1M, which are larger than LeMaitre Vascular quarterly revenues of $54.8M. NovoCure's net income of -$30.6M is lower than LeMaitre Vascular's net income of $11.1M. Notably, NovoCure's price-to-earnings ratio is -- while LeMaitre Vascular's PE ratio is 49.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 5.67x versus 9.71x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -19.71% compared to NovoCure's net margin of 14.25%. NovoCure's return on equity of -40.75% beat Insulet's return on equity of 49.55%.

NovoCure has a consensus price target of --, signalling upside risk potential of 14.79%. On the other hand Insulet has an analysts' consensus of $285.63 which suggests that it could grow by 8.47%. Given that NovoCure has higher upside potential than Insulet, analysts believe NovoCure is more attractive than Insulet.

NovoCure has a beta of 0.748, which suggesting that the stock is 25.16% less volatile than S&P 500. In comparison Insulet has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.859%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $155.1M, which are smaller than Insulet quarterly revenues of $543.9M. NovoCure's net income of -$30.6M is lower than Insulet's net income of $77.5M. Notably, NovoCure's price-to-earnings ratio is -- while Insulet's PE ratio is 45.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 5.67x versus 10.14x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.